表紙
市場調査レポート

中国のアトルバスタチン市場調査

Investigation Report on China Atorvastatin Market, 2010-2019

発行 China Research and Intelligence 商品コード 296114
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
中国のアトルバスタチン市場調査 Investigation Report on China Atorvastatin Market, 2010-2019
出版日: 2015年06月11日 ページ情報: 英文 30 Pages
概要

中国における血中脂質異常の有病率はほとんどの先進諸国よりも低いものの、中国人の平均血清総コレステロール(TC)レベルは経済発展とライフスタイルの変化によって向上しています。一方、中国において糖尿病と代謝症候群は極めて一般的です。統計によると18歳以上の層で血中脂質以上の有病率は20%を超えており、患者総数は2億人を上回ります。アトルバスタチン(Atorvastatin)は血中コレステロールを低下させるのに用いられています。CRIの調査によると、中国の病院市場における2005-2014年間のアトルバスタチンのCAGRは40%を上回っています。

当レポートでは、中国のアトルバスタチン市場について分析し、主要メーカーの市場シェア、中国の病院市場における価格変化・売上額、主要企業、および市場展望などを提供しており概略以下の構成でお届けします。

第1章 アトルバスタチン関連のコンセプト

  • 適応症
  • 世界市場における販売状況

第2章 中国におけるアトルバスタチンの市場概要

  • 特許状況
  • 主要メーカー
  • 市場規模

第3章 中国におけるアトルバスタチンの販売額調査

  • 売上額
    • 総売上額
    • 地域別
  • 販売量
    • 総販売量
    • 地域別

第4章 中国における主要アトルバスタチンメーカーの市場シェア調査

  • 市場シェア:売上額別
  • 市場シェア:売上高別

第5章 アトルバスタチンの市場規模調査:中国における投薬形態別

  • 市場シェア:売上額・投薬形態別
  • 市場シェア:売上高・投薬形態別

第6章 中国の病院市場におけるアトルバスタチンの基準価格

  • Beijing Jialin Pharmaceutical Co., Ltd.製造のアトルバスタチン価格
  • Topfond 製造のアトルバスタチンチン価格
  • Pfizer Co., Ltd.(Ireland) 製造のリピトール(Lipitor)価格
  • Pfizer Co., Ltd. (the U.S.A.) 製造のリピトール(Lipitor)価格
  • 価格
  • Pfizer Inc (Germany)のリピトール(Lipitor)価格

第7章 中国における主要アトルバスタチンメーカーの分析

  • Ebang Pharmaceutical
  • Pfizer
  • Topfond
  • Beijing Jialin Pharmaceutical Co., Ltd.

第8章 中国のアトルバスタチン市場の展望

  • 市場規模予測
  • 競合パターン予測

主要チャート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1506206

With the change of life styles brought about by the economic development and the rising incomes, the number of hyperlipidemia patients in China keeps growing, being estimated to reach 160-200 million in the near future.

Atorvastatin, a common drug that can lower blood cholesterol levels, was developed by Pfizer under the trade name of Lipitor. Boasting of nearly 20 years of use in over 100 countries in the real world, atorvastation has proved its efficacy and safety in hundreds of clinical tests and hundreds of millions of clinical medications. Large amounts of evidences and clinical practices have confirmed that atorvastation (10-80 mg) has strong effects in reducing low-density lipoprotein cholesterol (LDL-C). For patients with coronary heart disease, ischemic stroke, diabetes and hypertension, atorvastation is proved to reduce the number of cases of major cardiovascular diseases safely. By the end of 2014, the sales value of atorvastation has surpassed USD 100 billion around the world, creating a fabulous miracle among all the medicines for sale.

After entering China, atorvastatin develops fast with annual sales value rising from less than CNY 70 million in 2005 to CNY 1.374 billion in 2014 and CAGR reaching up to 41% during 2005-2014. Atorvastatin enjoys a vast demand in China. And such companies as Pfizer Inc (Ireland), Pfizer Inc (the US), Topfond and Beijing Jialin Pharmaceutical Co., Ltd occupy the market, among which Pfizer (the US) has the largest market share of about 65% in 2014 with sales value reaching up to CNY 895 million.

As the number of hyperlipidemia patients keeps growing, the sales value of atorvastatin is expected to increase in the next few years.

Readers can get at least the following information from this report:

  • sales status of atorvastatin in China
  • price of atorvastatin in Chinese market
  • major manufacturers of atorvastatin in Chinese market
  • share of dosage forms of atorvastatin in China
  • market outlook of atorvastatin in China

The author suggests the following groups of people purchase this report:

  • manufacturers of cardiovascular drugs
  • investors/ research institutions interested in China cardiovascular drug market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Atorvastatin

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Atorvastatin in China

  • 2.1. Patent and Approval Status of Atorvastatin in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Atorvastatin in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Atorvastatin in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Atorvastatin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Atorvastatin in Chinese Hospitals in 2014

  • 6.1. Beijing Jialin Pharmaceutical Co., Ltd (Trade Name: A Le)
  • 6.3. Topfond (Trade Name: You Jia)

6.4Pfizer Inc (Ireland) (Trade Name: Lipitor)

  • 6.5. Pfizer Inc(the US) (Trade Name: Lipitor)
  • 6.6. Pfizer Inc (Germany) (Trade Name: Lipitor)

7. Major Manufacturers of Atorvastatin in Chinese Market , 2010-2014

  • 7.1. Ebang Pharmaceutical
  • 7.2. Pfizer Inc
  • 7.3. Topfond
  • 7.4. Beijing Jialin Pharmaceutical Co., Ltd

8. Market Outlook of Atorvastatin in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Atorvastatin in China
  • Chart Approval Information of Atorvastatin in China
  • Chart Sales Status of Atorvastatin in China
  • Chart Sales Value of Atorvastatin in China, 2010-2014
  • Chart Sales Value of Atorvastatin in Some Regions in China, 2010-2014
  • Chart Sales Volume of Atorvastatin in China, 2010-2014
  • Chart Market Share of TOP4 Manufacturers of Atorvastatin for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Atorvastatin Made by Pfizer (the US) in China, 2010-2014
  • Chart Sales Value and Market Share of Atorvastatin Made by Beijing Jialin in China, 2010-2014
  • Chart Sales Value and Market Share of Atorvastatin Made by Pfizer (Ireland) in China, 2010-2014
  • Chart Sales Value and Market Share of Atorvastatin Made by Topfond in China, 2010-2014
  • Chart Sales Value and Market Share of Atorvastatin Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Atorvastatin Capsules in China, 2010-2014
  • Chart Price of Atorvastatin Made by Beijing Jialin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Atorvastatin Made by Topfond in Some Chinese Cities in 2014
  • Chart Price of Atorvastatin Made by Pfizer Inc (IR) in Some Chinese Cities in 2014
  • Chart Price of Atorvastatin Made by Pfizer Inc (the US) in Some Chinese Cities in 2014
  • Chart Price of Atorvastatin Made by Pfizer Inc (Germany) in Some Chinese Cities in 2014
Back to Top